dual-specific domain antibody therapy (Domantis/Abbott)

N/A

Report date: 2025/03/18 20:00:05

Base Information

Drug Namedual-specific domain antibody therapy (Domantis/Abbott)
Drug Alias Namedomain antibody therapy (Domantis/Abbott)dAb therapy (Domantis/Abbott)DSAb therapy (Domantis/Abbott)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragmentBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionInterleukin-1 alpha inhibitorsInterleukin-1 beta inhibitors
TargetsInterleukin-1 alphaInterleukin-1 beta
Therapy Area/IndicationsInflammation
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesDomantis Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAbbott LaboratoriesDomantis Ltd
Active IndicationsN/A
Inactive IndicationsInflammation

Other Information

ATC CodeN/A
Related LinksN/A